JP2007513164A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513164A5
JP2007513164A5 JP2006542711A JP2006542711A JP2007513164A5 JP 2007513164 A5 JP2007513164 A5 JP 2007513164A5 JP 2006542711 A JP2006542711 A JP 2006542711A JP 2006542711 A JP2006542711 A JP 2006542711A JP 2007513164 A5 JP2007513164 A5 JP 2007513164A5
Authority
JP
Japan
Prior art keywords
aminoisoindoline
dioxopiperidin
oxo
dioxo
dioxopiperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006542711A
Other languages
English (en)
Japanese (ja)
Other versions
JP5089170B2 (ja
JP2007513164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/040226 external-priority patent/WO2005055929A2/en
Publication of JP2007513164A publication Critical patent/JP2007513164A/ja
Publication of JP2007513164A5 publication Critical patent/JP2007513164A5/ja
Application granted granted Critical
Publication of JP5089170B2 publication Critical patent/JP5089170B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006542711A 2003-12-02 2004-12-02 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物 Expired - Fee Related JP5089170B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52691003P 2003-12-02 2003-12-02
US60/526,910 2003-12-02
PCT/US2004/040226 WO2005055929A2 (en) 2003-12-02 2004-12-02 Methods and compositions for the treatment and management of hemoglobinopathy and anemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011129684A Division JP2011207906A (ja) 2003-12-02 2011-06-10 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2007513164A JP2007513164A (ja) 2007-05-24
JP2007513164A5 true JP2007513164A5 (https=) 2008-02-07
JP5089170B2 JP5089170B2 (ja) 2012-12-05

Family

ID=34676680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006542711A Expired - Fee Related JP5089170B2 (ja) 2003-12-02 2004-12-02 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物
JP2011129684A Abandoned JP2011207906A (ja) 2003-12-02 2011-06-10 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011129684A Abandoned JP2011207906A (ja) 2003-12-02 2011-06-10 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物

Country Status (13)

Country Link
US (1) US20050143420A1 (https=)
EP (1) EP1694328A4 (https=)
JP (2) JP5089170B2 (https=)
KR (3) KR20060109979A (https=)
CN (2) CN1913896B (https=)
AU (2) AU2004296765B2 (https=)
BR (1) BRPI0417186A (https=)
CA (1) CA2547570A1 (https=)
IL (1) IL176020A0 (https=)
MX (1) MXPA06006061A (https=)
NZ (1) NZ548049A (https=)
WO (1) WO2005055929A2 (https=)
ZA (1) ZA200604815B (https=)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
EP3246396B1 (en) * 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US6942802B2 (en) * 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
JP2005522215A (ja) * 2002-04-12 2005-07-28 セルジーン・コーポレーション 幹細胞及び前駆細胞の分化のモジュレーション、アッセイ、並びにそれらの使用
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1496878A4 (en) * 2002-04-12 2007-12-26 Celgene Corp TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS
AU2003298775B2 (en) * 2002-11-26 2008-07-17 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
CA2560221C (en) * 2004-03-22 2010-12-07 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20050239842A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
ZA200704890B (en) * 2004-11-23 2008-09-25 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
DK1957633T3 (en) 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
CN101326281A (zh) * 2005-10-13 2008-12-17 人类起源公司 用源自胎盘的干细胞制备少突胶质细胞
CN101389754A (zh) 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
PT2471904T (pt) 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
CA2633980A1 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
CA2652888A1 (en) * 2006-05-26 2007-12-06 Celgene Corporation Methods and compositions using immunomodulatory compounds in combination therapy
CN101501185A (zh) * 2006-06-09 2009-08-05 人类起源公司 胎盘巢(placental niche)及其培养干细胞的用途
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
ZA200902233B (en) 2006-10-23 2010-07-28 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
EP3763376A1 (en) 2007-02-12 2021-01-13 Celularity, Inc. Treatment of inflammatory diseases using placental stem cells
AU2008216748A1 (en) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
CA2704710C (en) 2007-09-26 2016-02-02 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
NZ599825A (en) 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
BRPI0705396B1 (pt) * 2007-12-12 2021-10-05 Universidade Estadual De Campinas - Unicamp Compostos derivados ftalimídicos
JP2011510983A (ja) * 2008-01-29 2011-04-07 セルジーン コーポレイション Ｃｄ５９のレベルを調節するための、免疫調節化合物を使用する方法
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
WO2010021715A1 (en) 2008-08-20 2010-02-25 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
PT2358697E (pt) 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
AU2009316541B2 (en) 2008-11-19 2015-08-06 Celularity Inc. Amnion derived adherent cells
BRPI0921371A2 (pt) * 2008-11-25 2014-11-18 Otsuka Pharmaceutica Co Ltd Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas.
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
BRPI1007855B1 (pt) 2009-05-19 2020-03-10 Celgene Corporation Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
US8586360B2 (en) 2009-07-02 2013-11-19 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
BR112012015129A2 (pt) 2009-12-22 2019-09-24 Celgene Corp "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
DK3284818T3 (da) 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
LT2556145T (lt) 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
ES2666746T3 (es) 2010-07-13 2018-05-07 Anthrogenesis Corporation Métodos para generar linfocitos citolíticos naturales
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
EP2663549B1 (en) 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
JP6104896B2 (ja) 2011-06-01 2017-03-29 アントフロゲネシス コーポレーション 胎盤幹細胞を使用する疼痛の治療
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
RU2627471C2 (ru) 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
RS60415B1 (sr) 2011-12-27 2020-07-31 Amgen (Europe) GmbH Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
WO2013102142A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
ES2885769T3 (es) 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
EP2922838B1 (en) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
CN115137753A (zh) 2013-02-05 2022-10-04 细胞结构公司 来自胎盘的自然杀伤细胞
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105209469A (zh) * 2013-03-15 2015-12-30 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (en) 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112015025252A2 (pt) 2013-04-02 2017-07-18 Celgene Corp métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
ES2860648T5 (es) 2014-02-07 2024-11-27 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
AU2019294835B2 (en) * 2018-06-29 2025-04-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
US20220347186A1 (en) * 2019-09-27 2022-11-03 The University Of Chicago Methods and compositions for treating sickle cell disease and thalassemia
PY2217419A (es) 2021-03-15 2022-09-27 Novartis Ag Derivados de pirazolopiridina y sus usos
EP4612128A4 (en) 2022-11-04 2025-09-10 Bristol Myers Squibb Co COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862002A (en) * 1962-05-08 1975-01-21 Sanfar Lab Inc Production of physiologically active placental substances
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4798824A (en) * 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5284766A (en) * 1989-02-10 1994-02-08 Kao Corporation Bed material for cell culture
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5192312A (en) * 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
EP0691988B1 (en) * 1993-03-31 2002-10-02 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5599705A (en) * 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
CA2192103C (en) * 1994-06-06 2002-02-05 Arnold I. Caplan Biomatrix for tissue regeneration
US6174333B1 (en) * 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
US6103522A (en) * 1994-07-20 2000-08-15 Fred Hutchinson Cancer Research Center Human marrow stromal cell lines which sustain hematopoiesis
PT793714E (pt) * 1994-11-16 2002-12-31 Amgen Inc Utilizacao do factor de celulas estaminais e do receptor de interleucina 6 soluvel para a expansao ex vivo de celulas hematopoieticas multipotentes
US5874301A (en) * 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5695998A (en) * 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5716616A (en) * 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5733541A (en) * 1995-04-21 1998-03-31 The Regent Of The University Of Michigan Hematopoietic cells: compositions and methods
US5925567A (en) * 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
US5858782A (en) * 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
US6337387B1 (en) * 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen
US5919176A (en) * 1996-05-14 1999-07-06 Children's Hospital Medical Center Of Northern California Apparatus and method for collecting blood from an umbilical cord
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6358737B1 (en) * 1996-07-31 2002-03-19 Board Of Regents, The University Of Texas System Osteocyte cell lines
US5916202A (en) * 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US5879318A (en) * 1997-08-18 1999-03-09 Npbi International B.V. Method of and closed system for collecting and processing umbilical cord blood
AU9127098A (en) * 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
TR200101502T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
EP1108011A2 (en) * 1998-06-08 2001-06-20 Osiris Therapeutics, Inc. In vitro maintenance of hematopoietic stem cells
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US20030007954A1 (en) * 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US7160724B2 (en) * 2000-03-09 2007-01-09 University Of South Florida Human cord blood as a source of neural tissue for repair of the brain and spinal cord
US7282366B2 (en) * 2000-04-27 2007-10-16 Geron Corporation Hepatocytes for therapy and drug screening made from embryonic stem cells
AU2001261474B2 (en) * 2000-05-15 2006-03-09 Celgene Corporation Compositions and methods for the treatment of cancer
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
ATE374609T1 (de) * 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
DK1349918T3 (da) * 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US6987184B2 (en) * 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
WO2003012432A1 (en) * 2001-08-02 2003-02-13 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin and anti-tumor necrosis factor alpha combination therapy
US20030044977A1 (en) * 2001-08-10 2003-03-06 Norio Sakuragawa Human stem cells originated from human amniotic mesenchymal cell layer
US20040018178A1 (en) * 2002-01-22 2004-01-29 Advanced Cell Technology Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2752124A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN1668733A (zh) * 2002-05-30 2005-09-14 细胞基因公司 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法
US7422736B2 (en) * 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
WO2005001080A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US7569385B2 (en) * 2003-08-14 2009-08-04 The Regents Of The University Of California Multipotent amniotic fetal stem cells
US20060004043A1 (en) * 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
US7147626B2 (en) * 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
CA2593549C (en) * 2005-01-07 2016-04-26 Wake Forest University Health Sciences Regeneration of pancreatic islets by amniotic fluid stem cell therapy
WO2006091766A2 (en) * 2005-02-24 2006-08-31 Jau-Nan Lee Human trophoblast stem cells and use thereof
BRPI0611739A2 (pt) * 2005-06-10 2011-12-20 Celgene Corp colágeno de atelopeptìdeo, composição, método e kit para aumentar, avolumar ou substituir tecido de um mamìfero, e, processos para preparar e para reticular colágeno de atelopeptìdeo, e para reduzir a quantidade de partìculas virais em uma composição de colágeno
AU2006265601A1 (en) * 2005-06-30 2007-01-11 Anthrogenesis Corporation Repair of tympanic membrane using placenta derived collagen biofabric
US7928280B2 (en) * 2005-07-13 2011-04-19 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
US20070021762A1 (en) * 2005-07-13 2007-01-25 Qing Liu Ocular plug formed from placenta derived collagen biofabric
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
PT2471904T (pt) * 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
CN101501185A (zh) * 2006-06-09 2009-08-05 人类起源公司 胎盘巢(placental niche)及其培养干细胞的用途
KR20240052847A (ko) * 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
WO2010021715A1 (en) * 2008-08-20 2010-02-25 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
CA2734446C (en) * 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations

Similar Documents

Publication Publication Date Title
JP2007513164A5 (https=)
IL181674A0 (en) Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
NO2018028I2 (no) Kombinasjonen alogliptin og pioglitazon, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
NO20053245D0 (no) Tabletter med modifisert frigjoring av bupropionhydroklorid.
AP2006003585A0 (en) Delayed release dosage forms.
IL183963A0 (en) 1 - aminocyclohexane - derivatives for the treatment of multiple sclerosis, emotional liability and pseudobulbar affect
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
SI1765793T1 (sl) Anacetrapib in ostali CETP inhibitorji
ZA200704163B (en) Oral medicament for the modified release of at least one active principle, in a multimicrocapsule form
CL2007002494A1 (es) Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.
ATA4292004A (de) Automatisches tablettenabfüllverfahren und -system
DE602005011326D1 (de) Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid
EP1747775A4 (en) DISPERSIBLE MONTMORILLONITE TABLET AND ITS MANUFACTURE
DK1763301T3 (da) Faste formlegemer indeholdende aktivstoffer til udvortes anvendelse mod parasitter hos dyr
WO2007078271A3 (en) Lansoprazole orally disintegrating tablets
WO2009086813A3 (de) Vorrichtung zur reinigung des mundraums
WO2007075980A3 (en) Lansoprazole orally disintegrating tablets
DK1899256T3 (da) Løfteindretning
SI1791872T1 (sl) Biotinilirani heksadekasaharidi, farmacevtski sestavki in njihova uporaba
ATE469652T1 (de) Depsipeptide zur verhinderung vertikaler endoparasiten-infektionen
NL1023797A1 (nl) Farmaceutische doseringsvorm die zwangerschapsvriendelijke onderscheidingstekens draagt.
BRPI0924735A2 (pt) composição oral, artigo de dosagem portátil, métodos para preparar uma composição oral, para controlar a liberação de um agente edulcorante em uma cavidade oral, e para intensificar e/ou prolongar a sensação de flavor em uma cavidade oral, e, uso de um polímero.
ZA201003177B (en) Tetriacyclodipyranyl coumarins and the anti-hiv and anti-tuberculosis uses thereof
NL1029524A1 (nl) Filtratie-inrichting en werkwijze voor het gebruik hiervan.
RU2007105808A (ru) Способ профилактики острых респираторных инфекций у детей с аллергическими заболеваниями респираторного тракта